The University of Chicago Header Logo

Connection

Stuart Sprague to Calcium

Back to Details
This is a "connection" page, showing publications Stuart Sprague has written about Calcium.
Stuart Sprague
Connection Strength
2.338
Calcium
  1. Women and CKD-mineral and bone disorder. Adv Chronic Kidney Dis. 2013 Sep; 20(5):423-6.
    View in: PubMed
    Score: 0.330
  2. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76.
    View in: PubMed
    Score: 0.250
  3. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007 Dec; 23(12):3167-75.
    View in: PubMed
    Score: 0.222
  4. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004 Oct 27; 78(8):1233-6.
    View in: PubMed
    Score: 0.179
  5. 1,25-Dihydroxyvitamin D3-induced calcium efflux from calvaria is mediated by protein kinase C. J Bone Miner Res. 1999 Nov; 14(11):1822-7.
    View in: PubMed
    Score: 0.127
  6. Parathyroid hormone-induced calcium efflux from cultured bone is mediated by protein kinase C translocation. Am J Physiol. 1996 Dec; 271(6 Pt 2):F1139-46.
    View in: PubMed
    Score: 0.103
  7. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325.
    View in: PubMed
    Score: 0.102
  8. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30.
    View in: PubMed
    Score: 0.092
  9. Greater inhibition of in vitro bone mineralization with metabolic than respiratory acidosis. Kidney Int. 1994 Oct; 46(4):1199-206.
    View in: PubMed
    Score: 0.089
  10. Beta 2-microglobulin induces calcium efflux from cultured neonatal mouse calvariae. Am J Physiol. 1992 Sep; 263(3 Pt 2):F540-5.
    View in: PubMed
    Score: 0.077
  11. Mechanism of aluminum-induced calcium efflux from cultured neonatal mouse calvariae. Am J Physiol. 1990 Mar; 258(3 Pt 2):F583-8.
    View in: PubMed
    Score: 0.065
  12. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):512-8.
    View in: PubMed
    Score: 0.064
  13. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8.
    View in: PubMed
    Score: 0.063
  14. Beta2-microglobulin stimulates osteoclast formation. Kidney Int. 2008 Jun; 73(11):1275-81.
    View in: PubMed
    Score: 0.057
  15. Abnormal bone and mineral metabolism in kidney transplant patients--a review. Am J Nephrol. 2008; 28(2):246-53.
    View in: PubMed
    Score: 0.055
  16. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106.
    View in: PubMed
    Score: 0.055
  17. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43.
    View in: PubMed
    Score: 0.052
  18. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54.
    View in: PubMed
    Score: 0.039
  19. Renal osteodystrophy in chronic renal failure. Semin Nephrol. 2002 Nov; 22(6):488-93.
    View in: PubMed
    Score: 0.039
  20. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001 Nov; 38(5 Suppl 5):S51-6.
    View in: PubMed
    Score: 0.036
  21. Glucose-induced inhibition of in vitro bone mineralization. Bone. 2001 Jan; 28(1):21-8.
    View in: PubMed
    Score: 0.034
  22. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis. 2000 Oct; 36(4):789-96.
    View in: PubMed
    Score: 0.034
  23. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000 May; 15(5):927-35.
    View in: PubMed
    Score: 0.033
  24. Role of interleukin-6 in beta2-microglobulin-induced bone mineral dissolution. Kidney Int. 2000 Apr; 57(4):1599-607.
    View in: PubMed
    Score: 0.033
  25. Effects of aluminum on bone surface ion composition. J Bone Miner Res. 1995 Dec; 10(12):1988-97.
    View in: PubMed
    Score: 0.024
  26. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016 Feb; 29(1):63-70.
    View in: PubMed
    Score: 0.023
  27. Aluminum inhibits bone nodule formation and calcification in vitro. Am J Physiol. 1993 May; 264(5 Pt 2):F882-90.
    View in: PubMed
    Score: 0.020
  28. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed? Semin Dial. 2007 Jan-Feb; 20(1):24-32.
    View in: PubMed
    Score: 0.013
  29. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93.
    View in: PubMed
    Score: 0.012
  30. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May; 43(5):877-90.
    View in: PubMed
    Score: 0.011
  31. Severe hypercalcemia following neonatal liver transplantation. Miner Electrolyte Metab. 1995; 21(6):428-30.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.